Search results for " Antibodies"

showing 10 items of 383 documents

Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG

2020

Introduction: The 2019 Coronavirus disease (COVID-19) has been characterized as a pandemic, representing a serious global public health emergency. Serological tests have been proposed as reliable tools for detecting Coronavirus SARS-CoV-2 antibodies in infected patients, especially for surveillance or epidemiological purposes. The aim of this study is to evaluate the agreement between the IgM/IgG rapid assays, based on lateral flow immunochromatographic assay, and the fully automated 2019-nCoV IgM and IgG, based on chemiluminescence immunoassay. Materials and methods: SARS-CoV-2 antibodies were measured with the BIOSYNEX COVID-19 BSS IgM/IgG test (BIOSYNEX, Illkirch-Graffenstaden, France) a…

Male030213 general clinical medicineClinical BiochemistryAntibodies Viralmedicine.disease_causeLikelihood ratios in diagnostic testinglaw.inventionSerologyCOVID-19 Testing0302 clinical medicinelawantibodiesMedicineCoronavirusImmunoassay0303 health sciencesbiologymedicine.diagnostic_testMiddle AgedantibodiePopulation SurveillanceFemaleAntibodyCLIACoronavirus InfectionsShort CommunicationConcordanceSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralBetacoronavirus03 medical and health sciencesimmunochromatographyHumansPandemicsAged030304 developmental biologyChemiluminescenceClinical Laboratory TechniquesSARS-CoV-2business.industryCOVID-19; serological test; antibodies; CLIA; immunochromatographyBiochemistry (medical)Reproducibility of ResultsCOVID-19serological testImmunoglobulin MImmunoglobulin GImmunoassayLuminescent MeasurementsImmunologybiology.proteinbusiness
researchProduct

Relapse risk factors in anti-N-methyl-D-aspartate receptor encephalitis

2019

Aim: To identify factors that may predict and affect the risk of relapse in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. Method: This was a retrospective study of an Italian cohort of patients with paediatric (≤18y) onset anti-NMDAR encephalitis. Results: Of the 62 children included (39 females; median age at onset 9y 10mo, range 1y 2mo–18y; onset between 2005 and 2018), 21 per cent relapsed (median two total events per relapsing patient, range 2–4). Time to first relapse was median 31.5 months (range 7–89mo). Severity at first relapse was lower than onset (median modified Rankin Scale [mRS] 3, range 2–4, vs median mRS 5, range 3–5; admission to intensive care unit: 0/10 vs 3/10…

Male030506 rehabilitationGastroenterologyCohort Studies0302 clinical medicineRetrospective StudieModified Rankin ScaleRecurrenceRisk FactorsChildrelapseAnti-N-Methyl-D-Aspartate Receptor EncephalitisHazard ratioItalyChild PreschoolCohortanti‐N‐methyl‐D‐aspartate receptor encephalitisFemale0305 other medical scienceEncephalitisHumanCohort studymedicine.medical_specialtyAdolescentSocio-culturaleanti-NMDAR antibodies03 medical and health sciencesanti-NMDARDevelopmental NeuroscienceInternal medicinemedicineAdolescent; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Child; Child Preschool; Cohort Studies; Female; Humans; Infant; Italy; Male; Recurrence; Retrospective Studies; Risk FactorsHumansPreschoolSurvival analysisRetrospective StudiesAutoimmune encephalitisbusiness.industryInfantRetrospective cohort studymedicine.diseaseanti-NMDAR antibodies autoimmune encephalitis anti‐N‐methyl‐D‐aspartate receptor encephalitisautoimmune encephalitisAnti-N-methyl-D-aspartate receptor encephalitis anti-NMDAR autoimmune encephalitis relapseAnti-N-Methyl-D-Aspartate Receptor EncephalitiPediatrics Perinatology and Child HealthNeurology (clinical)Cohort Studiebusiness030217 neurology & neurosurgery
researchProduct

Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with pneumonia. Mowgli Study Group.

2001

The most common clinical signs, host responses and radiographic patterns were studied in 203 Italian children hospitalized for community-acquired pneumonia in order to clarify the role of clinical and radiological characteristics in the diagnosis of Mycoplasma pneumoniae and/or Chlamydia pneumoniae infections. Antibody measurements in paired sera and polymerase chain reaction on nasopharyngeal aspirates were used to establish the diagnoses of acute. M. pneumoniae and C. pneumoniae infection, and the aetiologic data were correlated with the clinical, laboratory and radiographic data obtained on admission. No significant association was observed between evidence of M. pneumoniae and/or C. pne…

MaleAcute Disease; Pneumonia; Mycoplasma; Diagnosis; Differential; Humans; Nasopharynx; Child; Mycoplasma pneumoniae; Preschool; Polymerase Chain Reaction; Lung; Bacterial; Antibodies; Chlamydia Infections; Community-Acquired Infections; Chlamydophila pneumoniae; Adolescent; Male; FemaleAdolescentPolymerase Chain ReactionAntibodiesDiagnosis DifferentialMycoplasmachildrenChlamydia pneumoniaeNasopharynxDiagnosisPneumonia MycoplasmaPneumonia BacterialpneumoniaHumansPreschoolChildLungBacterialChlamydia InfectionsChlamydophila pneumoniaeAntibodies BacterialMycoplasma pneumoniaeCommunity-Acquired InfectionsRadiographyChild PreschoolDifferentialAcute DiseaseFemaleThe European respiratory journal
researchProduct

Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study

2011

Background: The long-term risk of neoplasia in Crohn's disease (CD) patients treated with infliximab is undefined. The aim was to assess, in a multicenter, matched-pair study, whether infliximab use in CD is associated with an increased frequency of neoplasia in the long term. Methods: A multicenter, long-term, matched-pair study was conducted in 12 referral inflammatory bowel disease (IBD) centers. An initial cohort of 808 CD patients, including 404 infliximab-treated (CD-IFX) and 404 matched CD controls never treated with infliximab (CD-C) studied from 1999 to 2004, was followed up for an additional 4 years (2004–2008). Cases and controls were matched for: sex, age (±5 years), CD site, fo…

MaleAdultmedicine.medical_specialtyTime FactorsCROHN'S DISEASECrohn’s disease infliximab cancer matched-pairInflammatory bowel diseaseGastroenterologyAntibodiesCohort StudiesGastrointestinal AgentsCrohn DiseaseInternal medicineNeoplasmsINFLIXIMABMonoclonalmedicineImmunology and AllergyHumanstherapeutic use Case-Control Studies Cohort Studies Crohn Diseaseetiology Survival Rate Time Factors Treatment OutcomeSurvival rateAgedCancer Infliximab Inflammatory bowel diseaseCrohn's diseasebusiness.industryGastroenterologyCase-control studyAntibodies MonoclonalCancerMiddle Ageddrug therapy Female Follow-Up Studies Gastrointestinal Agenttherapeutic use Humans Male Middle Aged Neoplasmmedicine.diseaseTreatment Outcome; Male; Time Factors; Survival Rate; Middle Aged; Female; Neoplasms; Gastrointestinal Agents; Humans; Cohort Studies; Follow-Up Studies; Aged; Adult; Antibodies Monoclonal; Case-Control Studies; Crohn DiseaseCANCERInfliximabSurgerySurvival RateSettore MED/18 - Chirurgia GeneraleTreatment OutcomeCase-Control StudiesCohortFemaleAdult Aged Antibodiebusinessmedicine.drugCohort studyFollow-Up Studies
researchProduct

Absence of Anti-Glomerular Basement Membrane Antibodies in 200 Patients With Systemic Lupus Erythematosus With or Without Lupus Nephritis: Results of…

2020

IntroductionAnti-glomerular basement membrane (GBM) antibodies are pathogenic antibodies first detected in renal-limited anti-GBM disease and in Goodpasture disease, the latter characterized by rapidly progressive crescentic glomerulonephritis combined with intra-alveolar hemorrhage. Studies have suggested that anti-GBM antibody positivity may be of interest in lupus nephritis (LN). Moreover, severe anti-GBM vasculitis cases in patients with systemic lupus erythematosus (SLE) have been described in the literature, but few studies have assessed the incidence of anti-GBM antibodies in SLE patients.ObjectiveThe main study objective was to determine if positive anti-GBM antibodies were present …

MaleAnti-Glomerular Basement Membrane Disease[SDV]Life Sciences [q-bio]Lupus nephritisAucunurologic and male genital diseasesSeverity of Illness IndexGastroenterologyanti-glomerular basement membrane antibodies0302 clinical medicinesystemic lupus erythematosusLupus Erythematosus SystemicImmunology and Allergy030212 general & internal medicineOriginal Researchmedicine.diagnostic_testbiologyanti-GBM glomerulonephritisGlomerular basement membraneIIfMiddle Aged3. Good healthTitermedicine.anatomical_structure[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleAntibodyVasculitisAdultlcsh:Immunologic diseases. Allergymedicine.medical_specialtyImmunology03 medical and health sciencesAntigenInternal medicineanti-GBM antibodiesmedicineHumansAutoantibodiesRetrospective Studies030203 arthritis & rheumatologylupus nephritisbusiness.industryGoodpasture diseasemedicine.diseaseCase-Control StudiesImmunoassaybiology.proteinbusinesslcsh:RC581-607BiomarkersFrontiers in Immunology
researchProduct

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

2010

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated. ©…

MaleAntibodieReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptRandomized controlled triallawimmune system diseasesOutcome Assessment Health CareMonoclonalImmunology and Allergyskin and connective tissue diseasesAntirheumatic AgentAntibodies MonoclonalAntirheumatic AgentsTreatment OutcomeAntirheumatic AgentsFemalemedicine.drugHumanReceptormusculoskeletal diseasesAdultAnkylosingmedicine.medical_specialtyImmunologyDrug Administration ScheduleOutcome Assessment (Health Care)RheumatologyInternal medicinemedicineHumansSpondylitis AnkylosingSpondylitisSpondylitiAnkylosing spondylitisbusiness.industryTumor Necrosis Factor-alphaAnkylosing spondylitis; Etanercept; Infliximab; Adult; Antibodies Monoclonal; Antirheumatic Agents; Drug Administration Schedule; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Male; Outcome Assessment (Health Care); Receptors Tumor Necrosis Factor; Spondylitis Ankylosing; Treatment Outcome; Tumor Necrosis Factor-alpha; Rheumatology; Immunology; Immunology and Allergymedicine.diseaseInfliximabRheumatologyInfliximabClinical trialAnkylosing spondylitistomatognathic diseasesImmunoglobulin GPhysical therapybusinessTumor Necrosis Factor
researchProduct

Development of an antibody-based capture enzyme-linked immunosorbent assay for detecting echinostoma caproni (trematoda) in experimentally infected r…

2003

The present study reports on the development of a coproantigen capture enzyme-linked immunosorbent assay (ELISA) for detecting Echinostoma caproni in experimentally infected rats. The capture ELISA was based on polyclonal rabbit antibodies that recognize excretory–secretory (ES) antigens. The detection limit of pure ES was 3 ng/ml in sample buffer and 60 ng/ml in fecal samples. The test was evaluated using a follow-up of 10 rats experimentally infected with 100 metacercariae of E. caproni, and the results were compared with those of other diagnostic methods such as parasitological examination and antibody titers determined by indirect ELISA. Coproantigens were detected in all the infected r…

MaleAntibodies HelminthEchinostoma caproniEnzyme-Linked Immunosorbent Assay:CIENCIAS DE LA VIDA [UNESCO]ExcretionFecesAntigenEchinostomaCoproantigen ExcretionUNESCO::CIENCIAS DE LA VIDAAnimalsRats WistarAntibodyEcology Evolution Behavior and SystematicsFecesEchinostomiasisbiology:CIENCIAS DE LA VIDA::Biología animal (Zoología) ::Parasitología animal [UNESCO]Antibody titerInfected ratsbiology.organism_classificationAntibody ; Echinostoma caproni ; Infected rats ; Coproantigen Excretion ; InmunosorbentVirologyRatsKineticsUNESCO::CIENCIAS DE LA VIDA::Biología animal (Zoología) ::Parasitología animalPolyclonal antibodiesAntigens HelminthImmunologybiology.proteinParasitologyRabbitsAntibodyTrematodaEchinostomaInmunosorbent
researchProduct

Kinetics of antibodies and antigens in serum of mice experimentally infected with echinostoma caproni (trematoda: echinostomatidae)

2005

The present study reports on the kinetics of antibodies and antigens in serum of mice experimentally infected with 75 metacercariae of Echinostoma caproni during the first 12 wk postinfection (wpi). Antibody titers in the serum of mice were determined by an indirect enzyme-linked immunosorbent assay (ELISA) using excretory/secretory (ES) antigens of E. caproni. The early detection of antibodies against ES antigens of E. caproni is feasible using indirect ELISA. Mice developed significant antibody responses at 2 wpi, and the values progressively increased until the end of the experiment. This may be related to the intestinal absorption of adult worm antigens that induces humoral responses. T…

MaleAntibodies HelminthEnzyme-Linked Immunosorbent AssayEchinostoma caproniImmunoglobulin GIntestinal absorptionAntibodies:CIENCIAS DE LA VIDA [UNESCO]MicrobiologyMiceAntigenEchinostomaUNESCO::CIENCIAS DE LA VIDAAnimalsAntigensEcology Evolution Behavior and SystematicsEchinostomiasisMice Inbred ICRbiologyBiomphalariaAntibody titer:CIENCIAS DE LA VIDA::Biología animal (Zoología) ::Parasitología animal [UNESCO]biology.organism_classificationUNESCO::CIENCIAS DE LA VIDA::Biología animal (Zoología) ::Parasitología animalDisease Models AnimalKineticsPolyclonal antibodiesAntibodies ; Antigens ; Echinostoma caproniAntigens HelminthImmunoglobulin GImmunologybiology.proteinParasitologyTrematodaEchinostomaAntibody
researchProduct

Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis …

2001

ABSTRACT The aim of this study was to compare pertussis-specific humoral and cellular immunity in children 5 years after a primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine (DTaP-HBV; InfanrixHepB; SmithKline Beecham) with immunity after natural infection. The subjects were 38 children aged 5 to 6 years who received DTaP-HBV at 3, 5, and 11 months of life and 21 subjects of similar ages and sex who acquired pertussis in the first year of life. Immunoglobulin G (IgG) antibody titers against Bordetella pertussis antigens, peripheral blood mononuclear cell-specific proliferation, and the secretion of cytokines were evaluated. Aft…

MaleBordetella pertussisCellular immunityTime FactorsHepatitis B vaccineWhooping CoughImmunologyMicrobiologyBordetella pertussisAntibodiesInterferon-gammaImmunitymedicineHumansHepatitis B VaccinesSingle-Blind MethodVaccines CombinedLymphocytesChildPreschoolDiphtheria-Tetanus-Pertussis VaccineWhooping coughHaemophilus VaccinesVaccinesbiologyVaccines; Combined; Interferon-gamma; Humans; Whooping Cough; Hepatitis B Vaccines; Child; Lymphocytes; Diphtheria-Tetanus-Pertussis Vaccine; Vaccination; Preschool; Bordetella pertussis; Single-Blind Method; Interleukin-2; Antibodies; Bacterial; Haemophilus Vaccines; Interleukin-4; Interleukin-5; Time Factors; Male; Female; Cell DivisionCombinedTetanusbusiness.industryDiphtheriaCELL-MEDIATED-IMMUNITYVaccinationBacterialbiology.organism_classificationmedicine.diseaseAntibodies BacterialVirologyVaccinationInfectious DiseasesChild PreschoolMicrobial Immunity and VaccinesImmunologyInterleukin-2FemaleParasitologyInterleukin-4Interleukin-5businessCell Division
researchProduct

One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients w…

2021

Abstract Introduction and objectives Implementation of a one-step strategy for diagnosis of active Hepatitis C virus (HCV) infection would encourage the early diagnosis and reduce the time to access antiviral treatments. The aim of this study was to evaluate the impact of a HCV one-step diagnosis compared to the traditional two-step protocol in terms of the time required for patients to be seen by specialists and the time taken to start antiviral treatment. Material and methods A comparative study was carried out to assess two diagnostic algorithms (one-step and two-step) for active HCV infection. Serological markers were quantified using the same serum sample to determine both anti-HCV ant…

MaleCare processmedicine.medical_specialtyReferralHepatitis C virusSpecialties of internal medicineViremiaHepacivirusmedicine.disease_causeAntiviral AgentsSerologyMultidisciplinary approachInterquartile rangeInternal medicineHCV-cAgmedicineTelematics referralHumansOne-stepViremiaActive hepatitisHepatologyHepatitis C virusbusiness.industryTwo-stepGeneral MedicineHepatitis C Antibodiesmedicine.diseaseHepatitis CTelemedicineRC581-951FemaleHepatitis C AntigensbusinessAnnals of hepatology
researchProduct